Kurzfassung

A randomized, controlled, multicenter, open label study with blinded assessment of efficacy of the humanized Anti-IL-23p19 Risankuzumab compared to fumaderm in subjects with moderate to severe plaque psoriasis who are naive to and candidates for systemic therapy